Related Experiment Videos
Nesiritide (Natrecor): a new treatment for acutely decompensated congestive heart failure
Katberine Colbert1, Margaret H Greene
1The Southside Regional Medical Center, Petersburg, Va, USA. kcolbert@ssrme.org
Critical Care Nursing Quarterly
|April 3, 2003
Abstract:
The care of the patient experiencing acutely decompensated congestive heart failure requires therapies that promote vasodilation and increase cardiac output while decreasing symptomatic hypotension and dysrhythmias. Nesiritide (Natrecor) is a new type of drug, recombinant human B-type natriuretic peptide (hBNP), approved for use in acutely decompensated congestive heart failure. The neurohormonal effects of endogenous BNP are reproduced by nesiritide. Indications, dosing, administration, and review of clinical trials are presented in this article.